{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:55Z","timestamp":1793730955115,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021716","name":"Universite Paris Cite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejca.2024.114290","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T03:57:18Z","timestamp":1724385438000},"page":"114290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["BRAF +\u00a0EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer"],"prefix":"10.1016","volume":"210","author":[{"given":"Margherita","family":"Ambrosini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Decraecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Alouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marmorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A","family":"Sinicrope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114290_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib2","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib3","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/annonc\/mdz208","article-title":"Prognosis of microsatellite instability and\/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies","volume":"30","author":"Taieb","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.annonc.2023.08.006","article-title":"Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT\/IDEA pooled analysis of seven trials","volume":"34","author":"Taieb","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib5","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2021.06.037","article-title":"Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study","volume":"155","author":"Antoniotti","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114290_bib7","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib8","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.114290_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/oncolo\/oyad082","article-title":"BRAFV600E\/RAS mutations and lynch syndrome in patients with MSI-H\/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"28","author":"Colle","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114290_bib10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114290_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1158\/1078-0432.CCR-1118-3","article-title":"BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer","volume":"10","author":"Deng","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.114290_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2024.114290_bib13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.114290_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2006.02549.x","article-title":"Classification of colorectal cancer based on correlation of clinical, morphological and molecular features","volume":"50","author":"Jass","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2024.114290_bib15","first-page":"120","article-title":"The CpG island methylator phenotype (CIMP) in colorectal cancer","volume":"6","author":"Mojarad","year":"2013","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"10.1016\/j.ejca.2024.114290_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib17","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114290_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.dld.2020.11.031","article-title":"Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial","volume":"53","author":"Ta\u00efeb","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejca.2024.114290_bib19","doi-asserted-by":"crossref","unstructured":"Andre T., Elez E., Van Cutsem E., Jensen L.H., Bennouna J., Mendez G., et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Https:\/\/DoiOrg\/101200\/JCO2024423_supplLBA768 2024;42:LBA768\u2013LBA768. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_SUPPL.LBA768.","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768"},{"key":"10.1016\/j.ejca.2024.114290_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.32879","article-title":"Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study","volume":"147","author":"Tougeron","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.114290_bib21","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114290_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2022.03.011","article-title":"Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series","volume":"168","author":"Hafliger","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114290_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100506","article-title":"Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience","volume":"7","author":"Boccaccino","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114290_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E -mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114290_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1816","article-title":"625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: an AGEO real-world multicentre study","volume":"34","author":"Gallois","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2005.02.7227","article-title":"Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors","volume":"24","author":"Buhard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114290_bib30","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/cam4.2205","article-title":"Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients","volume":"8","author":"Aaseb\u00f8 K","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2024.114290_bib31","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114290_bib32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1634\/theoncologist.2017-0289","article-title":"Outcome of mismatch repair\u2010deficient metastatic colorectal cancer: the mayo clinic experience","volume":"23","author":"Jin","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114290_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/bjc.2016.161","article-title":"Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114290_bib34","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114290_bib35","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.114290_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF -mutant melanoma: The DREAMseq trial - ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114290_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-44475-6","article-title":"Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial","volume":"15","author":"Ascierto","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.114290_bib38","doi-asserted-by":"crossref","unstructured":"Elez E., Kopetz S., Tabernero J., Bekaii-Saab T., Taieb J., Yoshino T., et al. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC. \u3008Https:\/\/DoiOrg\/102217\/Fon-2022\u20131249\u3009 2023. https:\/\/doi.org\/10.2217\/FON-2022\u20131249.","DOI":"10.2217\/fon-2022-1249"},{"issue":"2","key":"10.1016\/j.ejca.2024.114290_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:51:55Z","timestamp":1727121115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"alternative-id":["S0959804924009468"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114290","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF +\u00a0EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114290"}}